Current Status of Vascepa Trials
Vascepa (icosapent ethyl), approved for cardiovascular risk reduction, has no major new phase 3 clinical trials actively recruiting or recently announced as upcoming. Ongoing studies focus on niche applications like reducing inflammation in COVID-19 patients or exploring statin combinations, but most large-scale trials (e.g., REDUCE-IT) concluded years ago.[1]
What Existing Trials Are Running
A few smaller trials continue:
- NCT04640678 tests Vascepa with atorvastatin for lipid effects in high-risk patients; estimated completion in 2025.
- NCT05589836 examines icosapent ethyl for post-COVID inflammation; recruiting through mid-2025.
- Pediatric safety study NCT05511162 for hypertriglyceridemia wraps up in 2026.
These build on prior data rather than seeking new indications.[2][3]
Why Fewer New Trials Now
Amarin, Vascepa's maker, shifted focus post-2020 approval expansions and patent settlements. Resources target generics defense and marketing over big trials. No phase 3 cardiovascular outcomes trials are slated soon.[1][4]
Patent Timeline and Generic Impact
Vascepa's key patents expire in 2030 (U.S. composition-of-matter), with method-of-use patents challenged in ongoing litigation. Generic entries expected 2026-2030 could limit trial incentives. Check DrugPatentWatch.com for expirations and Paragraph IV challenges.[5]
Alternatives in the Pipeline
Competitors like olezarsen (Ionis/Takeda) and plozasiran (Amgen) have phase 3 trials for triglycerides/cardiovascular risk underway, potentially challenging Vascepa commercially.[6]
[1]: ClinicalTrials.gov search for "icosapent ethyl" (updated 2024).
[2]: ClinicalTrials.gov NCT04640678.
[3]: ClinicalTrials.gov NCT05589836.
[4]: Amarin Corp investor updates (Q2 2024).
[5]: DrugPatentWatch.com/icosapent-ethyl.
[6]: ClinicalTrials.gov searches for olezarsen/plozasiran (2024).